I think the GSK share price could help you retire early

The GSK share price looks to have the potential to produce large total returns for long-term investors in the years ahead.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Of all the 100 different stocks in the FTSE 100, I think the GSK (LSE: GSK) share price has more potential to help you retire early than most. 

It all comes down to the company’s defensive nature. 

GSK share price growth 

Healthcare is one of the world’s most defensive markets. The treatments and products produced by GSK will always be required, and as the population grows, so will demand. 

But there’s more to GSK that its existing portfolio of drugs and medications. The company also spends billions of pounds every year researching new treatments. These products are designed to combat existing diseases and viruses, as well as new threats. The group is always trying to think of new ways to treat old problems and to address new issues. 

Management also considers acquisitions regularly. These efforts should help the company maintain its edge in the global pharmaceutical industry, not just in the short term, but in the long run as well.

This is the primary reason why the GSK share price could make an excellent buy-and-forget investment. Its products will always be in demand, and demand will only grow over the long run. That means to a certain extent the business runs itself. 

The company’s consumer pharmaceuticals division is another positive factor. Management is planning to spin off this business in the near term, which could create a windfall for shareholders. A special dividend or shares in the business may be distributed to existing GSK share price holders. 

Income returns 

It’s also good news for income seekers. GSK’s defensive business model means that the company has a relatively stable and predictable income stream from operations. This supports an attractive dividend yield on the GSK share price. 

Indeed, over the past few months, many FTSE 100 businesses have been forced to cut or eliminate their dividends to conserve cash in the coronavirus crisis. GSK is one of the few companies in the index that has not taken this course of action.

As a result, at the time of writing the stock supports a dividend yield of 4.9%, above the FTSE 100 average of around 4%. This looks set to continue as the dividend is well covered by earnings per share. The dividend cover stands at 1.5.

Retire early 

All of the above suggests that the GSK share price may be an excellent buy for any investor’s retirement portfolio. 

Over the long term, earnings per share should grow at least in line with inflation. That implies the company can achieve long-run earnings growth of 3% or more. Coupled with its 4.9% dividend yield, these numbers infer that the stock can produce total returns of 7.9% in the long term. 

This rate of return is more than enough to help you grow your financial nest egg. According to my calculations, an investment of £200 a month growing at a rate of 7.9% per annum could grow to be worth as much as £300,000 after 30 years. 

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Are 76% off Vistry shares a once-in-a-decade opportunity?

Vistry shares are looking dirt-cheap on some metrics. Is this the kind of rare buying opportunity that only comes around…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Down 10% in a month with a near-7% yield — are Aviva shares the perfect ISA buy?

Harvey Jones says stock market volatility could give investors the opportunity to snap up Aviva shares at a reduced price…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

£5,000 invested in Diageo shares 1 month ago is now worth…

Diageo shares have dipped below £14 recently, taking the one-year fall to 31%. So why has one leading broker turned…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

Elon Musk could give Scottish Mortgage shares a huge boost!

Dr James Fox explains why Scottish Mortgage shares could benefit massively as Elon Musk looks to take SpaceX public later…

Read more »

Investing Articles

As Rolls-Royce and Babcock rocket, has the BAE Systems share price finally run out of juice?

Harvey Jones is astonised at recent sluggish performance of the BAE Systems share price and wonders if there is better…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Down 31% and with a P/E of 8.8, is this FTSE 100 share too cheap to ignore?

Berkeley's share price has collapsed to its cheapest in roughly 10 years. Is the FTSE share now too cheap to…

Read more »

Investing Articles

10 dirt-cheap shares to consider after the correction

Investors keen to contribute to their ISA allowance before Sunday's deadline have a brilliant opportunity to buy cheap shares due…

Read more »

UK supporters with flag
Investing Articles

Why I think this super-cheap growth stock will lead the charge when the FTSE 100 recovers

Harvey Jones is seriously excited by this FTSE 100 growth stock but he also cautions that it can be very…

Read more »